secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001559053-23-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena Q1 net loss widens to $46.9M; pipeline progress with PRX012, PRX005 data
--------------------------------------------------------------------------------

- Net loss of $46.9M ($0.89 per share) vs $36.3M ($0.78) in Q1 2022; revenue $2.2M from BMS collaboration.
- Cash position $688.4M; FY 2023 guidance: net cash used $213-229M, year-end cash ~$512M.
- PRX012 preclinical data at AD/PD showed 20-fold higher affinity vs lecanemab; PRX005 Phase 1 SAD met safety objective.
- Key milestones: PRX012 topline data year-end 2023; birtamimab Phase 3 AFFIRM-AL topline in 2024.
- R&D expenses rose to $44.8M from $27.3M driven by clinical trial costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905323000014/0001559053-23-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905323000014/prta-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001559053-23-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer